Immune cell therapy takes on stubborn autoimmune disease
NCT ID NCT07148791
First seen Sep 30, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This phase 2 trial tests a new treatment called anti-BCMA-CD19 CAR-T cells for adults with IgG4-related disease that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target and attack disease-causing cells. Nine participants will receive the treatment and be monitored for safety and disease activity over 26 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-BCMA-CD19 CAR-T cells (a personalized immune cell therapy made from the patient's own blood cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat IgG4-related disease, potentially reducing symptoms and disease activity.
What could go wrong
This is a very early, small trial with only 9 participants, so results may not apply to everyone. The therapy involves strong chemotherapy beforehand and carries risks like immune reactions and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.